Although it is recognized that ischemic stroke is a potent risk factor for vascular dementia, the influence of white matter lesions (WML) on cognitive function is less clear. In community-based MRI studies that have administered mental status tests to subjects who were free of clinically evident neurologic disease, a weak relationship between WML and generalized cognitive function has been reported. In studies that have administered neuropsychological test batteries, a stronger and more specific association has been recognized between WML and deficits in executive function, most likely due to the involvement of frontal-subcortical pathways. Cognitive deficits may be related to the total volume of the WML, with a threshold perhaps needing to be surpassed before such deficits are evident, but it is likely that the location of the WML also plays a role, with that threshold varying in association with the distribution of the lesions. Potential confounders of the results of previous studies include small, strategically located subcortical infarctions that may be masked by more extensive WML and other comorbid neurologic disorders, particularly Alzheimer’s disease. Future studies should be prospective, utilize standardized methods for structural and functional brain imaging, and administer comprehensive neuropsychological assessments in order to more rigorously investigate the relationship between evolving WML and declining cognitive functions.

1.
Pantoni L, Leys D, Fazekas F, Longstreth WT, Inzitari D, Wallin A, Filippi M, Scheltens P, Erkinjuntti T, Hachinski V: Role of white matter lesions in cognitive impairment of vascular origin. Alzheimer Dis Assoc Disord 1999;13(suppl 3):S49–S54.
2.
Desmond DW: Vascular dementia: A construct in evolution. Cerebrovasc Brain Metab Rev 1996;8:296–325.
3.
Pohjasvaara T, Erkinjuntti T, Ylikoski R, Hietanen M, Vataja R, Kaste M: Clinical determinants of poststroke dementia. Stroke 1998;29:75–81.
4.
Barba R, Martínez-Espinosa S, Rodríguez-García E, Pondal M, Vivancos J, Del Ser T: Poststroke dementia. Clinical features and risk factors. Stroke 2000;31:1494–1501.
5.
Desmond DW, Moroney JT, Paik MC, Sano M, Mohr JP, Aboumatar S, Tseng CL, Chan S, Williams JBW, Remien RH, Hauser WA, Stern Y: Frequency and clinical determinants of dementia after ischemic stroke. Neurology 2000;54:1124–1131.
6.
Longstreth WT, Manolio TA, Arnold A, Burke GL, Bryan N, Jungreis CA, Enright PL, O’Leary D, Fried L: Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3,301 elderly people. The Cardiovascular Health Study. Stroke 1996;27:1274–1282.
7.
Junqué C, Pujol J, Vendrell P, Bruna O, Jódar M, Ribas JC, Viñas J, Capdevila A, Marti-Vilalta JL: Leuko-araiosis on magnetic resonance imaging and speed of mental processing. Arch Neurol 1990;47:151–156.
8.
Schmidt R, Fazekas F, Offenbacher H, Dusek T, Zach E, Reinhart B, Grieshofer P, Freidl W, Eber B, Schumacher M, Koch M, Lechner H: Neuropsychologic correlates of MRI white matter hyperintensities: A study of 150 normal volunteers. Neurology 1993;43:2490–2494.
9.
Breteler MMB, van Amerongen NM, van Swieten JC, Claus JJ, Grobbee DE, van Gijn J, Hofman A, van Harskamp F: Cognitive correlates of ventricular enlargement and cerebral white matter lesions on magnetic resonance imaging. The Rotterdam Study. Stroke 1994;25:1109–1115.
10.
DeCarli C, Murphy DGM, Tranh M, Grady CL, Haxby JV, Gillette JA, Salerno JA, Gonzales-Aviles A, Horwitz B, Rapoport SI, Schapiro MB: The effect of white matter hyperintensity volume on brain structure, cognitive performance and cerebral metabolism of glucose in 51 healthy adults. Neurology 1995;45:2077–2084.
11.
Boone KB, Miller BL, Lesser IM, Mehringer CM, Hill-Gutierrez E, Goldberg MA, Berman NG: Neuropsychological correlates of white-matter lesions in healthy elderly subjects. A threshold effect. Arch Neurol 1992;49:549–554.
12.
de Groot JC, de Leeuw FE, Oudkerk M, van Gijn J, Hofman A, Jolles J, Breteler MMB: Cerebral white matter lesions and cognitive function: The Rotterdam Scan Study. Ann Neurol 2000;47:145–151.
13.
Ylikoski R, Ylikoski A, Erkinjuntti T, Sulkava R, Raininko R, Tilvis R: White matter changes in healthy elderly persons correlate with attention and speed of mental processing. Arch Neurol 1993;50:818–824.
14.
Fukui T, Sugita K, Sato Y, Takeuchi T, Tsukagoshi H: Cognitive functions in subjects with incidental cerebral hyperintensities. Eur Neurol 1994;34:272–276.
15.
Desmond DW, Moroney JT, Lynch T, Chan S, Chin SS, Shungu DC, Naini AB, Mohr JP: CADASIL in a North American family: Clinical, pathologic, and radiologic findings. Neurology 1998;51:844–849.
16.
Tatemichi TK, Desmond DW, Prohovnik I, Cross DT, Gropen TI, Mohr JP, Stern Y: Confusion and memory loss from capsular genu infarction: A thalamocortical disconnection syndrome? Neurology 1992;42:1966–1979.
17.
Tatemichi TK, Desmond DW, Prohovnik I: Strategic infarcts in vascular dementia. A clinical and brain imaging experience. Drug Res 1995;45:371–385.
18.
Schmidt R, Fazekas F, Kapeller P, Schmidt H, Hartung HP: MRI white matter hyperintensities. Three-year follow-up of the Austrian Stroke Prevention Study. Neurology 1999;53:132–139.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.